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Abstract The type 1 sigma receptor expressed in Xenopus
oocytes showed binding abilities for the sigma-1 ligands,
[3H](+)pentazocine and [3H]NE-100, with similar kinetic proper-
ties as observed in native tissue membranes. Amino acid
substitutions (Ser99Ala, Tyr103Phe and di-Leu105,106di-Ala)
in the transmembrane domain did not alter the expression levels
of the type 1 sigma receptor as determined by immunoblot
analysis using an anti-type 1 sigma receptor antiserum. By
contrast, ligand binding was significantly suppressed by the
substitutions. These findings provide evidence that the trans-
membrane domain of the type 1 sigma receptor plays a critical
role in ligand binding of this receptor.
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1. Introduction
Sigma receptors were initially postulated to account for the
psychotomimetic actions of N-allylnormetazocine (( þ )SKF-
10.047) [1]. Subsequent biochemical and pharmacological
studies using radioligands have demonstrated that the sigma
receptors are distinct from opioid or phencyclidine binding
sites, and then they can be classi¢ed into at least two subtypes
designated ‘sigma-1’ and ‘sigma-2’ [2]. In addition, lines of
evidence indicate that sigma receptors in the central nervous
system are involved in drug addiction and a¡ective disorders
[3,4] and those in the immune system are involved in immu-
noregulations [5]. Their physiological roles, however, remain
to be clari¢ed, and their endogenous ligands have also yet to
be determined.
Recently, cDNAs of the type 1 sigma receptor (SigmaR1)
were cloned, and subsequently, their amino acid sequences
were deduced [6^10]. The primary structure of SigmaR1 is
highly conserved among a variety of mammalian species and
tissues, indicating its importance in cellular functions. Inter-
estingly, a protein targeted by SR 31747A, a sigma ligand and
a novel immunosuppressant (or SR 31747A binding protein),
is very similar to SigmaR1 with respect to structural and
pharmacological pro¢les [11]. In addition, many antipsy-
chotics, antidepressants and immunosuppressants have some
a⁄nity for sigma receptors [2]. While pharmacological char-
acterization of sigma receptors using selective sigma-1 ligands
is being in progress, the structure-a⁄nity relationship of Sig-
maR1 remains to be established.
To address these issues at the molecular level, we cloned
SigmaR1 cDNA from guinea pig liver, and expressed it in
Xenopus oocytes by injection of cRNA derived from the
cDNA. Using highly selective sigma-1 ligands, (+)pentazocine
and N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-
ethylamine monohydrochloride (NE-100) [12], the e¡ects of
site-directed mutagenesis of SigmaR1 on ligand binding
were investigated.
2. Materials and methods
2.1. Materials
NE-100, [3H]NE-100 (speci¢c activity, 3145 GBq/mmol) and
[3H]azidoNE-100 (speci¢c activity, 3070 GBq/mmol) were synthesized
[12] in the Department of Organic Chemistry at the Research Center,
Taisho Pharmaceutical (Saitama, Japan). [3H](+)Pentazocine (speci¢c
activity, 2146 GBq/mmol) was purchased from New England Nuclear.
All other chemical reagents were of analytical grade.
2.2. cDNA cloning and sequencing
Based on the cDNA sequence for the guinea pig SigmaR1 [6], two
oligodeoxyribonucleotide primers were synthesized. The sense (S1)
and the antisense (S2) primers corresponded to amino acid residues
1^7 and 217^223, respectively: S1, TTCACTCGAGGTGATGCAGT-
GGGC(A/G/C/T)GT(A/G/C/T)GG(A/G/C/T)CG; S2, GGCTGGTC-
AAGGGTCTTG(A/G/C/T)CC(A/G)AA(A/G/C/T)AG(A/G)TA. The
¢rst cDNA strands were synthesized by the S2-primed reverse tran-
scription of total RNA from guinea pig liver using an RNA LA PCR
Kit (Takara, Japan). Polymerase chain reactions (PCR) were carried
out for 0.5 min at 94‡C, 0.5 min at 60‡C, and 1.5 min at 72‡C for
30 cycles, by adding the primer S1 to the ¢rst strand reaction mixture
containing the primer S2. The 700 bp products ampli¢ed by the PCR
were puri¢ed, treated with T4 DNA polymerase with the four dNTPs,
subcloned into the EcoRV site of pBluescript SK(3) (Stratagene) and
then subjected to nucleotide sequence analysis using a DNA sequencer
(ABI Prism 377, PE Applied Biosystems). The recombinant pBlue-
script plasmid carrying a cDNA encoding the entire coding sequence
of SigmaR1 was referred to as ‘pSR1’.
2.3. Construction of mutant SigmaR1
The genetic mutations of the transmembrane domain [7] of Sig-
maR1 were performed with PCR (see above) using the antisense prim-
er S2 together with the sense primer SM1, SM2, SM3 or SM4 (see
Fig. 1A). The primer SM1, CTTCTGCATGCCGCGCTGTCCGAG,
contains the point mutation (G) replacing the ¢rst codon TCG coding
for Ser-99 of SigmaR1 by GCG encoding Ala. The primer SM2,
CTTCTGCATGCCTCGCTGTCCGAGTATGTGGCGGCCTTCG-
GCACC, contains the point mutations (GC) replacing the ¢rst and
second codons of CTG and CTC coding for Leu-105 and Leu-106 by
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GCG and GCC encoding Ala, respectively. The primer SM3,
CTTCTGCATGCCGCGCTGTCCGAGTATGTGGCGGCCTTCG-
GCACC, contains the combined point mutations derived from the
primers SM1 and SM2. Finally, the primer SM4, CTTCTGCAT-
GCCTCGCTGTCCGAGTTTGTGCTGCTC, contains the point mu-
tation (T) replacing the second codon TAT coding for Tyr-103 by
TTT encoding Phe. The plasmid pSR1 (see above) was used as tem-
plate. The 390 bp products ampli¢ed by the PCR using a set of
primers of SM1/S2, SM2/S2, SM3/S2 and SM4/S2 were puri¢ed,
blunted with T4 DNA polymerase, digested with SphI, and cloned
into SphI/EcoRI (blunted) site of pSR1 in order to yield pSAR,
pLAR, pSLAR and pYFR, respectively.
Subcloning and mutagenesis procedures were veri¢ed by restriction
enzyme analysis and DNA sequencing.
2.4. Functional expression of wild-type and mutant SigmaR1
The 700 bp HindIII/EcoRI fragment containing the entire coding
region of wild-type SigmaR1 was excised from the plasmids pSR1,
blunted with T4 DNA polymerase, and inserted into the EcoRV site
of pSPA2 [13] to synthesis cRNA speci¢c for wild-type SigmaR1 in
vitro using a MEGAscript SP6 Kit (Ambion). The 80 bp SphI/BglII
fragment of the resulting pSPA2 plasmid was exchanged by the 80 bp
SphI/BglII fragment derived from pSAR, pLAR, pSLAR or pYFR to
synthesis mutant receptor cRNAs in vitro.
After removal of the follicular cell layer by treatment with 1 mg/ml
collagenase for 1.5 h at 20‡C [14], Xenopus oocytes were injected
either with 0.5 Wg/Wl of wild-type or mutant sigma-1 receptor cRNA
unless otherwise speci¢ed: the average volume of injection was V50
nl per oocyte. The injected oocytes were incubated for 3 days, and
then, subjected to immunoblot analysis and a binding assay.
2.5. Immunoblot analysis
A polyclonal antiserum (ASR1) was raised in New Zealand White
rabbits against a synthetic docosapeptide (PSR1: CSEVFYP-
GETVVHGPGEATAVE), corresponding to amino acid residues
143^163 of SigmaR1. An extra cysteine was added to the peptide
on the N-terminus for conjugation with keyhole limpet hemocyanin.
Membrane fractions were obtained from oocytes as described in
[15], and microsomal, mitochondrial and synaptosomal fractions
were prepared from rat brain as described in [16]. These fractions
(0.5 Wg) were separated by 12.5% SDS-PAGE and transferred to a
FluoroTrans membrane (Pall BioSupport) [17]. Membranes were
blocked overnight at 4‡C with 3% (w/v) BSA in TBS/Tw (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl and 0.05% Tween-20). For immu-
nostaining of SigmaR1, the antiserum ASR1 was diluted 500-fold in
TBS/Tw containing 0.1% BSA. Before incubation with membranes
(for 3 h at room temperature), the antiserum was pre-incubated
with or without 100 Wg/ml of the antigen peptide PSR1 for 1 h at
37‡C. Then, membranes were incubated with horseradish peroxidase-
(HRP-)conjugated goat anti-rabbit IgG (Biosource, at 1:2000 dilu-
tion). Labelled proteins were determined by diaminobenzidine-based
HRP products with heavy metal intensi¢cation [18].
2.6. Binding assays
Radioligand binding assays with [3H](+)pentazocine and [3H]NE-
100 were performed using oocyte membranes fractions according to
the methods as described previously [19,20]. Saturation experiments
were conducted over a concentration range of 2.0^15 nM
[3H](+)pentazocine, and NE-100 binding was carried out using 2.0
nM [3H]NE-100. Non-speci¢c binding was determined in the presence
of 1 WM of haloperidol. Protein concentrations were determined using
a Bio-Rad protein assay kit (Bio-Rad). The dissociation constant (Kd)
was determined using the computer program Ligand [21]. Statistical
data are represented by the mean þ S.E.M.
Photolabelling assays with [3H]azidoNE-100 were carried out using
primary neuronal cells in culture obtained from rat cerebral cortex
according to the procedures described [22].
3. Results and discussion
3.1. cDNA cloning of SigmaR1
Determination of the nucleotide and predicted amino acid
sequences of the 690 bp insert of clone pSR1 (see Section 2)
revealed three nucleotide changes from the sequence of guinea
pig SigmaR1 [6], which resulted in three amino acid changes
identical to the human version of SigmaR1 [7]: Val-71, Pro-
114 and Arg-115 were determined as Gly, Arg and Gly, en-
coded by GGA, CGC and GGC, respectively. Six other nu-
cleotide changes in the sequences were shown not to alter the
coding amino acid residues: C (12), G (15), C (18), A (339), C
(654) and C (657) of SigmaR1 [6] were G, T, T, C, A and T in
our clones, respectively. Thus, the insert of the clone pSR1
contained the cDNA sequence encoding SigmaR1.
3.2. Expression of wild-type and mutant SigmaR1 in Xenopus
oocytes
Aiming at identifying the regions on SigmaR1 that interact
with sigma-1 ligands, four kinds of mutants SigmaR1 were
generated and expressed in Xenopus oocytes (Fig. 1A). In
mutants ‘SA’ and ‘YF’, Ser-99 and Tyr-103 were substituted
by Ala and Phe, respectively. Mutant ‘LA’ had a substitution
of di-Ala for di-Leu 105 and 106, and mutant ‘SLA’ had an
additional substitution of Ala for Ser-99 on the mutant LA.
The positions of these point mutations were assigned to the
putative transmembrane domain of SigmaR1 [7] (Fig. 1A).
In oocytes injected with the wild-type SigmaR1 cRNA, the
antiserum ASR1 reacted with a polypeptide of 29 kDa (Fig.
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Fig. 1. A: Schematic representation of mutant SigmaR1 designated
as SA, LA, SLA and YF. The putative transmembrane domain [7]
is shaded in the amino acid sequence of SigmaR1. Amino acid sub-
stitutions on the mutant SigmaR1 are indicated by arrows. B: (left)
Immunoreactivities with the antiserum ASR1 to the membrane frac-
tions prepared from Xenopus oocytes without cRNA injection (con-
trol) or after injection of wild-type (Wt) or mutant (SA, LA, SLA
or YF) SigmaR1 cRNA. Note that immunoreactive 29 kDa poly-
peptides (arrow) are not appreciably detectable unless cRNA for
wild-type or mutant SigmaR1 is injected. B: (right) Immunoreactive
29 kDa polypeptides (arrow) with ASR1 in the microsomal, mito-
chondrial and synaptosomal fractions from rat brain, as indicated.
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1B, left, Wt: arrow). This immunoreactivity was abolished by
pre-incubation of ASR1 with the peptide antigen PSR1
(n = 3). Moreover, ASR1 scarcely reacted with the polypeptide
unless oocytes were injected with SigmaR1 cRNA (Fig. 1B,
left, control). These results indicate that an immunoreactive
polypeptide of 29 kDa was recognized speci¢cally by the anti-
serum against the synthetic SigmaR1 peptide. In addition, the
antiserum ASR1 mainly reacted with a polypeptide of 29 kDa
(Fig. 1B, right, arrow) in rat brain microsomal (microsome),
mitochondrial (mitochondria) and synaptosomal (synapto-
some) fractions, the reactivities that were also abolished by
the pre-incubation of ASR1 with the peptide PSR1 (n = 3).
The 29 kDa polypeptide was most predominant in the micro-
somal fraction. The size of this immunoreactive polypeptide
corresponded well with the size of SigmaR1 reported [6] or the
size (29^30 kDa) of a native sigma-1 ligand binding protein
determined by selective covalent labelling of rat cortical neu-
ronal culture using [3H]azidoNE-100, an azido analog of the
sigma-1 speci¢c ligand NE-100 [12], as a photoactive radio-
ligand (n = 3).
As shown in Fig. 1B (left : SA, LA, SLA and YF), the
antiserum ASR1 reacted with a 29 kDa polypeptide in oocytes
injected with each mutant SigmaR1 cRNA as well. These
immunoreactivities were also abolished by pre-absorption of
ASR1 with the antigen peptide PSR1 (n = 3). Moreover, levels
of the immunoreactivities in the various mutant SigmaR1
were comparable with those in wild-type SigmaR1 (Fig. 1B,
Wt). Thus, it is suggested that mutations in the transmem-
brane domain of SigmaR1 do not a¡ect the expression of
the receptors per se.
3.3. Ligand binding activities in wild-type and mutant SigmaR1
To test whether mutations in the transmembrane domain
a¡ect binding activities for sigma-1 ligands, saturation binding
assays with [3H](+)pentazocine, a prototype agonist of sigma-
1 receptors, on Xenopus oocyte membranes were carried out
after injection of wild-type or mutant SigmaR1 cRNA. Bind-
ing of [3H](+)pentazocine to membranes prepared from oo-
cytes injected with wild-type SigmaR1 cRNA was markedly
increased (Fig. 2A, Wt) as compared with those from oocytes
without injection of SigmaR1 cRNA (Fig. 2A, control). When
[3H]NE-100, a sigma-1 antagonist, was used as a radioligand
instead of [3H](+)pentazocine, an increase in the amount of
binding was also produced by injection of wild-type SigmaR1
cRNA (Fig. 2B, control and Wt). Therefore, these ¢ndings
were consistent with the results that the immunoreactivities
with the SigmaR1 antiserum were not observed in Xenopus
oocytes unless SigmaR1 cRNA was injected (Fig. 1B, left).
Scatchard analysis of the binding to membranes prepared
from oocytes expressing wild-type SigmaR1 resulted in a lin-
ear plot (Fig. 2A, Wt) suggesting a single binding site for the
exogenously-expressed SigmaR1 in Xenopus oocytes as re-
ported in native tissue membranes [23]. The dissociation con-
stant (Kd) was 11.7 þ 1.2 nM (n = 6) (Table 1). This Kd value
was also comparable with that (14.2 þ 2.3 nM, n = 3) obtained
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Fig. 2. A: Representative scatchard plots of [3H](+)pentazocine
binding using membranes (2.0^2.7 Wg) prepared from Xenopus oo-
cytes without cRNA injection (control) or after injection of wild-
type (Wt) or mutant (SLA or YF) SigmaR1 cRNA (see Fig. 1A).
B: Speci¢c [3H]NE-100 binding in membranes (0.7^14.1 Wg) from
Xenopus oocytes without cRNA injection (control) or after injection
of wild-type (Wt) or mutant (SA, LA, SLA or YF) SigmaR1 cRNA
(see Fig. 1A). The data are represented as the ratio of [3H]NE-100
binding to that obtained from oocytes injected with wild-type Sig-
maR1 cRNA (Wt). The original bindings before normalization were
2.43 þ 0.59, 26.8 þ 10.7, 19.0 þ 9.2, 10.6 þ 4.5, 4.0 þ 1.4 and 4.3 þ 1.9
pmol/mg protein for the control, Wt, SA, LA, SLA and YF, respec-
tively (n = 5). To lessen seasonal or individual variations [14], a set
of oocytes injected with cRNAs for wild-type and mutant SigmaR1
was prepared at the same time for binding assays.
Table 1
E¡ects of amino acid substitutions in the transmembrane domain of
SigmaR1 on the binding a⁄nity for [3H](+)pentazocine
SigmaR1 Kd (nM)
None (control) 30.4 þ 12.6 (3)
Wt 11.7 þ 1.2 (6)
SA 36.6 þ 3.9* (5)
LA 42.0 þ 4.2* (5)
SLA 9.9 þ 1.6 (5)
YF 49.0 þ 8.0* (6)
The dissociation constants (Kd) were determined by saturation bind-
ing of [3H](+)pentazocine using membrane fractions prepared from
Xenopus oocytes without cRNA injection (none (control)) or after
injection of wild-type (Wt) or mutant (SA, LA, SLA or YF) SigmaR1
cRNA (see Figs. 1A and 2A). The number of experiments is indicated
in parentheses. *P6 0.01 relative to wild-type SigmaR1.
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from binding of [3H](+)pentazocine to rat crude synaptosomal
membranes prepared from rat cerebral cortex. Thus, all these
¢ndings indicate that exogenous wild-type SigmaR1 was func-
tionally expressed in Xenopus oocytes.
As in the case of wild-type SigmaR1, binding analysis with
[3H](+)pentazocine was performed using membranes from oo-
cytes expressing each mutant receptor. A decrease in the af-
¢nity of [3H](+)pentazocine for SigmaR1 was produced in
these three kinds of mutants, SA, LA and YF (Table 1, Fig.
2A: SA, LA and YF) as compared with Wt SigmaR1. The
rank order of binding a⁄nity for [3H](+)pentazocine among
these mutant SigmaR1 was SAsLAsYF (Table 1). By con-
trast, the mutant SLA, having combined mutations in SA and
LA, did not show a marked change in the a⁄nity (Table 1,
Fig. 2A). Considering the results that both wild-type and four
kinds of mutant SigmaR1 were expressed to a similar extent
as immunoreactive polypeptides, it seems likely that these
changes in the ligand binding a⁄nity by the mutations are
due to direct perturbation of the sigma ligand-SigmaR1 inter-
actions.
To further investigate the ligand interactions, the sigma-1
antagonist [3H]NE-100 was used as a radioligand for the bind-
ing assay. These mutations in the transmembrane domain of
SigmaR1 also diminished speci¢c [3H]NE-100 binding (Fig.
2B: SA, LA and YF) as compared with wild-type SigmaR1
(Fig. 2B, Wt). The rank order of binding ability for [3H]NE-
100 was SAsLAsYF, which was identical to that for
[3H](+)pentazocine, indicating that these three kinds of muta-
tions exert similar e¡ects on both agonist and antagonist
binding to SigmaR1. Among these mutations, the single YF
mutation yielded a most appreciable decrease in binding ac-
tivities for both [3H](+)pentazocine and [3H]NE-100. There-
fore, it is indicated that the amino acid residue, Tyr-103, in
the transmembrane domain is critical for ligand binding to
SigmaR1.
Unlike [3H](+)pentazocine binding, [3H]NE-100 binding
was almost completely abolished in the mutant SLA (Fig.
2B, SLA). This discrepancy between (+)pentazocine and
NE-100 binding in the mutant SLA implies the presence of
di¡erent recognition site(s) in the transmembrane domain of
SigmaR1 for di¡erent ligands such as agonist and antagonist.
The amino acid residues, Ser-99, Leu-105 and Leu-106 in the
domain might play an important role in distinguishing each
ligand through interaction with the ligand. Further studies
using additional sigma-1 ligands and site-directed mutagenesis
will be necessary to determine the direct interaction between
speci¢c amino acid residues on SigmaR1 and speci¢c sigma-1
ligands.
Taken together, all these ¢ndings indicate that the segment
of amino acid residues Ser-99^Leu-106 in the putative trans-
membrane domain of SigmaR1 serves as a crucial structural
determinant in receptor-ligand interaction without changing
the expression level of SigmaR1. By analogy to G protein-
coupled receptors including L-adrenergic [24], muscarinic ace-
tylcholine [25,26] and dopamine D2 [27] receptors, it is plau-
sible to assume that a ligand binding pocket for signal trans-
duction lies in the transmembrane domain of SigmaR1.
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